Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Tuesday that it is planning to invest an additional USD450m and create around 100 new jobs to expand its manufacturing capacity at the firm's Research Triangle Park facility in North Carolina.
The expansion includes additional parenteral filling, device assembly and packaging capacity in order to support an increased demand for the company's incretin products that treat diabetes.
When the facility is completely operational in 2027, this phase of the project is likely to create around 100 new jobs, mainly manufacturing personnel, who will use advanced technology to develop incretin treatments and medical devices.
Langhua Pharmaceutical passes US FDA's on-site inspection
Arecor signs collaboration deal with global pharma partner
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Sterotherapeutics launches Phase 2 clinical trial of ST-002 for Cushing's Syndrome
FDA accepts Alvotech and Teva's application for Eylea biosimilar
Owens & Minor launches ByramConnect digital health platform for diabetes management
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Teladoc Health to acquire Catapult Health to enhance integrated care offerings
NLS Pharmaceutics and Kadimastem announce shareholder approval for merger
ImmunoPrecise Antibodies announces development of AI-designed GLP-1 therapies for diabetes